Allogene Therapeutics Inc (ALLO) fair value: what the stock is really worth
We calculate from audited financials what Allogene Therapeutics Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
- Compare price with fair valuebelow fair value = cheap, above = expensive
- Check the quality50 and up solid, 75 and up strong
- Watch it or check another stockalert when fair value or trend changes
At a glance
Allogene Therapeutics Inc
ALLO · US
Below-average quality, and trading another 422% above our fair value of $0.3315.
As of Aug 27, 2026, the fair value of Allogene Therapeutics Inc is $0.3315 per share against a price of $1.73, so the fair value sits 81% below the price. A model estimate from reported figures, not an analyst target.
Fair value as of: Aug 27, 2026
From 1 valuation models · updated 14 days ago
Share price −17.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.4165). The favourable scenario is already priced in.
- Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.2210 to $0.4165) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range $0.9528 – $27.64 · fair‑value band $0.2210 – $0.4165 · the $1.73 price screens above the $0.3315 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Allogene Therapeutics Inc (ALLO) currently trades at $1.73, while our model-based Fair Value estimate is $0.3315, implying the stock looks roughly 421.9% overvalued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
It earns a return on equity of −52.3%. Net debt stands at $31.6M. Fundamentals as of Aug 27, 2026
Scenario range: $0.2210 (bear) to $0.4165 (bull), the price of $1.73 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 61% below its 52-week high and 76% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −81%, ALLO screens richer than that median.
Fair Value models
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
All 1 models by family
Notify me when ALLO reaches fair value
Put ALLO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Full company description
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Allogene Therapeutics Inc reported revenue of $0 in FY2025 versus $38.5M in FY2021. Reported net income was −$191M in FY2025.
ALLO screens 422% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
- Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
- Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy
Peer Group
Biotechnology · 633 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $546.12 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $827.72 | $594.40 | −28% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,452,000 KRW | 1,055,793 KRW | −27% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE 22UA | €80.60 | €52.92 | −34% |
Compare Allogene Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Allogene Therapeutics Inc (ALLO) overvalued or undervalued?
What is the fair value of ALLO?
What is the quality score of ALLO?
What is the price target for Allogene Therapeutics Inc (ALLO)?
What is the Allogene Therapeutics Inc stock forecast for 2026?
What is the net profit margin of ALLO?
What is the intrinsic value of Allogene Therapeutics Inc (ALLO)?
Is Allogene Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ALLO?
How much is Allogene Therapeutics Inc worth?
What do the bullish and bearish scenarios say about ALLO?
How solid is the balance sheet of Allogene Therapeutics Inc (ALLO)?
How far is ALLO from its 52-week high?
Which stocks are comparable to Allogene Therapeutics Inc?
Is Allogene Therapeutics Inc stock attractive at the current price?
How is the fair value of ALLO calculated?
Watch Allogene Therapeutics Inc in the live analysis
One click puts Allogene Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.